An observational study in Lp(A), Hypercholesterolemia and Cardiovascular Diseases, sponsored by School of Medicine. National University of Cuyo. Recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by School of Medicine. National University of Cuyo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hypercholesterolemia with a site in Argentina — 3 open to participants now, 7 under way, 5 of them phase 3. Hypercholesterolemia · Argentina.
Among the 19 studies in Hypercholesterolemia with a site in Argentina, this one is one of 4 that started in 2024, is one of 2 observational ones, and was the 15th registered.
1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 19 studies in Hypercholesterolemia with a site in Argentina are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Novartis Pharmaceuticals · Sites in Argentina, United States, Austria and 20 more countries
Ages 6–11
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is close to the median of 1,000 across 145 observational studies indexed under Hypercholesterolemia.
Median enrollment 1,743 across the 17 interventional studies, 650 across the 2 observational. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 9 most frequent:
School of Medicine. National University of Cuyo is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
School of Medicine. National University of Cuyo has 1 study filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypercholesterolemia with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Hypercholesterolemia with a site in Argentina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Argentine Registry on Lipoprotein(a) (LP(a)), orchestrated by the Argentine Group for LP(a) Study, stands as a pioneering and extensive prospective initiative. This registry systematically collects geolocation data, including patient postal codes, demographic information, and a multifaceted array of health parameters to unravel the intricate associations surrounding LP(a) levels.
The dataset encompasses diverse patient characteristics, ranging from standard metrics like blood pressure, weight, and race to broader factors such as diabetes, smoking habits, menopausal status, and hypothyroidism. This holistic approach enables a nuanced exploration of the interplay between LP(a) levels and various risk factors, providing invaluable insights for both clinical and public health considerations.
One distinctive feature of this registry lies in its focus on medication history, shedding light on the impact of routine pharmaceutical interventions on LP(a) profiles. Additionally, it delves into the intricate web of inflammatory diseases, recognizing their potential role in LP(a) modulation.
Genetic predispositions are meticulously examined, with a specific emphasis on identifying homozygous and heterozygous variants associated with hypercholesterolemia. This genetic dimension adds a layer of complexity to the understanding of LP(a) dynamics, contributing significantly to the ongoing discourse on cardiovascular risk.
The prospective nature of this registry allows for dynamic analyses, fostering a continuous exploration of emerging patterns and trends. By amalgamating geographical, clinical, and genetic data, the Argentine LP(a) Registry emerges as a comprehensive platform poised to unlock novel facets of LP(a) biology and its implications for cardiovascular health. As the dataset matures, it holds the promise of guiding personalized interventions and refining risk stratification strategies, thereby advancing the landscape of preventive cardiovascular care.
Adult patients residing in Argentina
Inclusion Criteria: Adult patients with validated Lp(a) values -
Exclusion Criteria: Associated pathologies that can increase the Lp(a) value in a non-specific manner
-
prevalence of high level of Lp(a)
prevalence of high level of Lp(a)
Time frame: 2 years
Started Feb 2024 (actual). Primary completion is estimated for Feb 2026, 24 months after the start.
Of 51 observational studies under Hypercholesterolemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
School of Medicine. National University of Cuyo